SEC Form 4 · accession 0001127602-15-021141
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Jun 18, 2015
Accepted (ET)
Jun 22, 2015 · 4:38 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 18, 2015 | S | 3,500 | $14.00 | D | 149,644 | D | |
| Common StockF1 | Jun 18, 2015 | M | 3,100 | $3.78 | A | 152,744 | D | |
| Common StockF1 | Jun 18, 2015 | M | 3,100 | $3.78 | A | 155,844 | D | |
| Common StockF1 | Jun 18, 2015 | S | 3,100 | $14.25 | D | 152,744 | D | |
| Common StockF1 | Jun 18, 2015 | S | 3,100 | $13.50 | D | 149,644 | D | |
| Common StockF1 | Jun 19, 2015 | S | 3,500 | $15.00 | D | 146,144 | D | |
| Common StockF1 | Jun 19, 2015 | M | 3,175 | $3.78 | A | 149,319 | D | |
| Common StockF1 | Jun 19, 2015 | S | 3,175 | $15.00 | D | 146,144 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $3.78 | Jun 18, 2015 | M | 3,100 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 3,100 | 108,035 | D |
| Stock Option (Right to Buy)F1 | $3.78 | Jun 18, 2015 | M | 3,100 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 3,100 | 104,935 | D |
| Stock Option (Right to Buy)F1 | $3.78 | Jun 19, 2015 | M | 3,175 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 3,175 | 101,760 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2014.